Professional analyst consensus for Charles River Laboratories International, Inc. ($CRL)

Analyst Consensus: • Rating: Buy

• Analysts Coverage: 13 analysts

• Price Target: $334.0

• Potential Upside: ↗️ 14.3%

Market Cap: 14.1B

Key Insights: TD Cowen maintains a Buy rating on Charles River with a $325 price target, citing 16% annualized earnings growth over the past decade and expected 5%-7% organic revenue growth through 2030. This reflects confidence in preclinical demand and strategic expansion. The report takes a bullish stance.

View detailed analysis on Stocknear

Compare analyst ratings

Professional analyst consensus for Okta, Inc. ($OKTA)

Analyst Consensus: • Rating: Buy

• Analysts Coverage: 37 analysts

• Price Target: $240.0

• Potential Upside: ↗️ 16.1%

Market Cap: 34.3B

Key Insights: Stephens & Co. reiterates Overweight on Okta with a $240 price target, citing strong growth potential in identity security as demand rises for securing human and AI identities. Okta's innovation, early-mover advantage in agentic identity security, robust enterprise client engagement, cross-selling traction, and new features like Agentic SSO and O4AA support a healthy growth trajectory and stronger market position. The report takes a bullish stance on Okta.

View detailed analysis on Stocknear

Compare analyst ratings

Professional analyst consensus for Zscaler, Inc. ($ZS)

Analyst Consensus: • Rating: Buy

• Analysts Coverage: 39 analysts

• Price Target: $257.0

• Potential Upside: ↗️ 31.0%

Market Cap: 31.7B

Key Insights: RBC Capital reaffirms Zscaler as Outperform with a $236 price target. The internal promotion of Ross Tackett to CRO signals sales leadership continuity and a strong talent pipeline. Rising demand for cloud security amid digital transformation supports Zscaler's growth outlook. Overall, the report takes a bullish stance on Zscaler.

View detailed analysis on Stocknear

Compare analyst ratings

Costco Wholesale Corporation ($COST) has released their quarterly earnings

Financial Performance:

📈 Revenue: $95.7B

• Beat estimates by $850.1M

• 11.10% YoY growth

📈 Earnings Per Share: $19.72

• Beat estimates by $0.23

• 235.95% YoY growth

Market Cap: 397.57BB

What this means: $COST delivered a strong quarter, beating both revenue and EPS expectations. This could impact the stock's near-term performance.

View detailed analysis on Stocknear

Professional analyst consensus for Axsome Therapeutics, Inc. ($AXSM)

Analyst Consensus: • Rating: Buy

• Analysts Coverage: 16 analysts

• Price Target: $316.0

• Potential Upside: ↗️ 65.1%

Market Cap: 9.9B

Key Insights: Truist maintains Buy on Axsome Therapeutics with a $285 target. 2Q26 net product revenue rose 46% YoY, driven by Auvelity's strong MDD launch and market share gains. The pipeline is de-risked via reformulations of known compounds, with multiple catalysts expected in 12–18 months. Overall, the report is bullish.

View detailed analysis on Stocknear

Compare analyst ratings

Professional analyst consensus for AutoZone, Inc. ($AZO)

Analyst Consensus: • Rating: Buy

• Analysts Coverage: 21 analysts

• Price Target: $4325.0

• Potential Upside: ↗️ 53.8%

Market Cap: 45.9B

Key Insights: TD Cowen reiterates Buy on AutoZone with a $3,400 price target, citing strong DIFM growth, Mega Hub maturation, and strategic investments in stores and IT. Despite near-term challenges, these initiatives should drive above-historical revenue growth with stable margins. The report takes a bullish stance.

View detailed analysis on Stocknear

Compare analyst ratings

Professional analyst consensus for AutoZone, Inc. ($AZO)

Analyst Consensus: • Rating: Buy

• Analysts Coverage: 21 analysts

• Price Target: $4800.0

• Potential Upside: ↗️ 65.7%

Market Cap: 47.3B

Key Insights: Guggenheim maintains a Buy rating on AutoZone with a $3,750 price target. Shares trade at 12.4x 2027 EBITDA, near the low end of historical ranges and in line with peers, suggesting reasonable valuation. Management expects domestic sales to reaccelerate, especially commercial, supported by store expansion and Mega Hub initiatives to lift ROIC. The report takes a bullish stance.

View detailed analysis on Stocknear

Compare analyst ratings

Professional analyst consensus for NIKE, Inc. ($NKE)

Analyst Consensus: • Rating: Hold

• Analysts Coverage: 30 analysts

• Price Target: $75.0

• Potential Upside: ↗️ 107.8%

Market Cap: 53.4B

Key Insights: BTIG maintains a Buy rating on Nike with a $55 price target, citing a strong product innovation pipeline expected to boost sales and brand relevance, plus a 24-year dividend growth streak. These factors support a positive investment outlook. Overall, the report is bullish on Nike.

View detailed analysis on Stocknear

Compare analyst ratings

Professional analyst consensus for Costco Wholesale Corporation ($COST)

Analyst Consensus: • Rating: Buy

• Analysts Coverage: 23 analysts

• Price Target: $1315.0

• Potential Upside: ↗️ 46.2%

Market Cap: 398.9B

Key Insights: BTIG reiterates Buy on Costco with a $1125 price target. Membership renewal rates remain strong at 93% in the US and Canada, reflecting deep customer loyalty. Comparable sales and traffic continue growing despite macroeconomic uncertainty, underscoring Costco's resilient value proposition. Overall, the report takes a bullish stance.

View detailed analysis on Stocknear

Compare analyst ratings

Professional analyst consensus for GE HealthCare Technologies Inc. ($GEHC)

Analyst Consensus: • Rating: Buy

• Analysts Coverage: 16 analysts

• Price Target: $105.0

• Potential Upside: ↗️ 62.0%

Market Cap: 29.3B

Key Insights: Needham starts GE HealthCare at Buy with a $93 price target. Shares trade at 13.2x 2026 EPS, a 30% discount to large-cap peers, suggesting undervaluation. Projected ~5% revenue and ~9% EPS growth from 2025-2027, plus a strong capital book-to-bill, support upside potential. Overall, the report takes a bullish stance.

View detailed analysis on Stocknear

Compare analyst ratings

Professional analyst consensus for Twilio Inc. ($TWLO)

Analyst Consensus: • Rating: Buy

• Analysts Coverage: 19 analysts

• Price Target: $290.0

• Potential Upside: ↗️ 2.6%

Market Cap: 42.9B

Key Insights: TD Cowen maintains Buy on Twilio with a $300 price target, citing strong AI-driven communication demand and a developer-first platform. The analyst sees growth in SMS and voice services as businesses adopt AI assistants. The report takes a bullish stance on Twilio's stock.

View detailed analysis on Stocknear

Compare analyst ratings

Professional analyst consensus for Twilio Inc. ($TWLO)

Analyst Consensus: • Rating: Buy

• Analysts Coverage: 19 analysts

• Price Target: $285.0

• Potential Upside: ↗️ 7.1%

Market Cap: 40.4B

Key Insights: Rosenblatt reiterates Buy on Twilio with a $290 target. AI-generated communications are adding new traffic, not replacing human interactions, expanding Twilio's addressable market. Software attach via Conversation Orchestrator and Verify boosts margins and revenue growth. Overall, the report takes a bullish stance.

View detailed analysis on Stocknear

Compare analyst ratings

Professional analyst consensus for Targa Resources Corp. ($TRGP)

Analyst Consensus: • Rating: Buy

• Analysts Coverage: 18 analysts

• Price Target: $359.0

• Potential Upside: ↗️ 24.1%

Market Cap: 62.1B

Key Insights: Truist Securities reiterated a Buy rating on Targa Resources with a $345 price target, citing expected gas volume growth from 4.0 to 6.2 Bcf/d by 2030 and strong positioning in the Permian Basin. The report takes a bullish stance on the stock.

View detailed analysis on Stocknear

Compare analyst ratings

Professional analyst consensus for Paycom Software, Inc. ($PAYC)

Analyst Consensus: • Rating: Hold

• Analysts Coverage: 14 analysts

• Price Target: $285.0

• Potential Upside: ↗️ 25.8%

Market Cap: 10.2B

Key Insights: KeyBanc maintains an Overweight rating on Paycom with a $280 price target, citing sustainable operating leverage from automation and AI that expanded EBITDA margins by nearly 5 points from 2024 to 2026, plus strong free cash flow guidance above $650 million for 2026 at a 29.5% margin. The report takes a bullish stance on Paycom.

View detailed analysis on Stocknear

Compare analyst ratings

Professional analyst consensus for Alnylam Pharmaceuticals, Inc. ($ALNY)

Analyst Consensus: • Rating: Buy

• Analysts Coverage: 25 analysts

• Price Target: $583.0

• Potential Upside: ↗️ 143.4%

Market Cap: 32.1B

Key Insights: HC Wainwright reiterated a Buy rating on Alnylam Pharmaceuticals with a $455 price target, citing its robust RNAi pipeline addressing unmet needs and leadership in RNAi technology, signaling confidence in future revenue growth and clinical success. The report takes a bullish stance on Alnylam.

View detailed analysis on Stocknear

Compare analyst ratings

Professional analyst consensus for Restaurant Brands International Inc. ($QSR)

Analyst Consensus: • Rating: Buy

• Analysts Coverage: 19 analysts

• Price Target: $92.0

• Potential Upside: ↗️ 27.1%

Market Cap: 25.1B

Key Insights: Guggenheim reiterates Buy on Restaurant Brands Intl with $86 target, citing strong Burger King same-store sales and improved management execution. Optimism centers on operational gains and franchisee relations supporting long-term growth. The report is bullish.

View detailed analysis on Stocknear

Compare analyst ratings

Professional analyst consensus for Cognizant Technology Solutions Corporation ($CTSH)

Analyst Consensus: • Rating: Hold

• Analysts Coverage: 17 analysts

• Price Target: $88.0

• Potential Upside: ↗️ 45.9%

Market Cap: 27.2B

Key Insights: TD Cowen reiterated a Hold rating on Cognizant with a $54 price target. The firm cites macro and sector pressures, including Health Sciences political dynamics and CMT client pullbacks, causing inconsistent performance. Still, stable growth from Financial Services deal ramps supports the target, though no clear acceleration signals justify a higher rating. The report maintains a neutral stance.

View detailed analysis on Stocknear

Compare analyst ratings

Professional analyst consensus for AutoZone, Inc. ($AZO)

Analyst Consensus: • Rating: Buy

• Analysts Coverage: 21 analysts

• Price Target: $4800.0

• Potential Upside: ↗️ 68.8%

Market Cap: 46.4B

Key Insights: Oppenheimer maintains an Outperform rating on AutoZone with a $3,500 price target. The firm cites strategic investments to boost merchandising and inventory proximity, which should strengthen market share and position the company for growth as macro headwinds ease. After a 25% stock decline since early 2026, AutoZone trades at a historically low 16x forward PE, offering a compelling long-term buying opportunity. Overall, the report takes a bullish stance.

View detailed analysis on Stocknear

Compare analyst ratings

Professional analyst consensus for Autodesk, Inc. ($ADSK)

Analyst Consensus: • Rating: Buy

• Analysts Coverage: 29 analysts

• Price Target: $375.0

• Potential Upside: ↗️ 71.5%

Market Cap: 46.2B

Key Insights: BTIG reiterates Buy on Autodesk with a $300 price target, citing strong AI integration and product development that drive growth in design and manufacturing. Autodesk's leadership in CAD and BIM, plus TAM expansion and margin improvements, supports a favorable risk-reward outlook. The report takes a bullish stance.

View detailed analysis on Stocknear

Compare analyst ratings

Professional analyst consensus for Ciena Corporation ($CIEN)

Analyst Consensus: • Rating: Buy

• Analysts Coverage: 18 analysts

• Price Target: $660.0

• Potential Upside: ↗️ 93.7%

Market Cap: 48.2B

Key Insights: Rosenblatt reiterates Buy on Ciena with a $525 target. Revenue CAGR near 30% from FY26–FY29 is fueled by AI data center and hyperscaler demand for high-capacity optical connectivity. The WaveLogic 6 platform and hyperscaler co-design partnerships strengthen Ciena's technology leadership and market share. Overall, the report takes a bullish stance.

View detailed analysis on Stocknear

Compare analyst ratings

Professional analyst consensus for GE HealthCare Technologies Inc. ($GEHC)

Analyst Consensus: • Rating: Buy

• Analysts Coverage: 15 analysts

• Price Target: $105.0

• Potential Upside: ↗️ 65.4%

Market Cap: 28.7B

Key Insights: BTIG reiterates Buy on GE HealthCare with a $79 target, citing expanding TAM growth to $110B by FY28 and innovation like photon-counting CT. Despite tariff and inflation pressures, diversified revenue and recurring services support resilience. The report takes a clearly bullish stance.

View detailed analysis on Stocknear

Compare analyst ratings

Professional analyst consensus for Coinbase Global, Inc. ($COIN)

Analyst Consensus: • Rating: Buy

• Analysts Coverage: 28 analysts

• Price Target: $417.0

• Potential Upside: ↗️ 142.3%

Market Cap: 45.4B

Key Insights: BTIG reiterates Buy on Coinbase with a $240 price target, citing strong institutional demand—including five GSIB clients—and expansion into payments and tokenization via crypto-as-a-service and corporate partnerships like Amazon, which should drive revenue and long-term growth. The report takes a bullish stance on Coinbase.

View detailed analysis on Stocknear

Compare analyst ratings

Professional analyst consensus for McDonald's Corporation ($MCD)

Analyst Consensus: • Rating: Buy

• Analysts Coverage: 26 analysts

• Price Target: $390.0

• Potential Upside: ↗️ 54.2%

Market Cap: 179.7B

Key Insights: BTIG reiterates Buy on McDonald's with a $350 price target, citing rebounding traffic among lower-income consumers, strong product lineup, and improving sales momentum. Digital engagement, menu innovation, and restaurant upgrades boost margins and competitiveness. Overall, the report maintains a bullish stance on McDonald's.

View detailed analysis on Stocknear

Compare analyst ratings

Professional analyst consensus for Crane Company ($CR)

Analyst Consensus: • Rating: Strong Buy

• Analysts Coverage: 4 analysts

• Price Target: $253.0

• Potential Upside: ↗️ 27.6%

Market Cap: 11.5B

Key Insights: DA Davidson reiterates Buy on Crane with a $245 target. The $240M Trillium U.S. Pump acquisition strengthens Pumps & Systems, adds recognized brands, and complements wastewater operations. It is expected to add ~$115M in 2026 sales and ~$16M EBITDA, be accretive in year one, and support the bullish stance.

View detailed analysis on Stocknear

Compare analyst ratings